Bathen J, Madsen S
Medisinsk avdeling Regionsykehuset i Trondheim.
Tidsskr Nor Laegeforen. 1998 Oct 30;118(26):4086-7.
Sotalol is a betablocker with additional antiarrythmic properties. Its pharmacokinetic properties may lead to increased serum levels of the drug in patients with reduced kidney function. We report on a case in which kidney failure in a patient using sotalol for paroxysmal atrial fibrillation gave rise to torsade de pointes ventricular tachycardia and, eventually, sudden death. Gradual prolongation of the QT interval suggested an overdose of sotalol. Sotalol has been commonly used in cases of angina pectoris and hypertension. The recently published SWORD study has, however, changed the indications for its use, and sotalol should now only be used in cases of severe supraventricular and ventricular arrythmias.
索他洛尔是一种具有额外抗心律失常特性的β受体阻滞剂。其药代动力学特性可能导致肾功能减退患者的药物血清水平升高。我们报告了一例使用索他洛尔治疗阵发性心房颤动的患者,肾衰竭引发尖端扭转型室性心动过速,最终导致猝死。QT间期逐渐延长提示索他洛尔过量。索他洛尔常用于心绞痛和高血压病例。然而,最近发表的SWORD研究改变了其使用指征,现在索他洛尔仅应用于严重的室上性和室性心律失常病例。